Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Vulvar lichen sclerosus (LS) is a chronic inflammatory dermatosis which can progress to precursor lesion differentiated vulvar intraepithelial neoplasia (dVIN) and vulvar squamous cell carcinoma (VSCC). The risk of developing recurrent vulvar cancer following LS-associated VSCC is high. Evidence suggests that treatment of LS with topical corticosteroids (TCS) can prevent progression to dVIN, VSCC and recurrences. However, current guidelines do not give any recommendation on the management of LS following surgery for VSCC. The aim of this study was to conduct a survey among all registered gynaecologic oncologists (GOs) in the Netherlands to evaluate the current management of LS patients without a history of VSCC (LS) and patients with LS following surgery for VSCC (LS).
Methods: An online survey was distributed to all registered GOs in the Netherlands. Primary outcome measures were the frequency, type and duration of TCS treatment prescribed for LS and LS patients, separately. As a secondary outcome measure, reasons for treating or not treating patients with LS and LS with TCS were analysed.
Results: Forty-four GOs completed the survey, resulting in a response rate of 75%. TCS were prescribed more often to patients with LS as compared to patients with LS (86% 52%, respectively, < 0.001). If treatment was initiated, ultra-potent (class IV) TCS were most commonly prescribed for an indefinite period of time for both patient groups. The most reported reason for treating patients in both groups with TCS was symptoms, followed by clinical aspects of the lesion and prevention of progression to dVIN and VSCC.
Conclusion: The majority of GOs who participated in our study endorse the utilisation of long-term ultra-potent TCS therapy in both patients with LS and LS. Nevertheless, Dutch GOs are currently prescribing TCS more frequently to patients with LS than to patients with LS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01443615.2023.2294330 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinico-demographic characteristics of pemphigus foliaceus: Retrospective analysis of clinic-based data of 103 patients in a non-endemic location.
Clin Exp Dermatol
September 2025
Department of Dermatology, Venereology and Leprology; Postgraduate Institute of Medical Education and Research; Chandigarh, India.
Background: Pemphigus foliaceus (PF) is an uncommon autoimmune blistering disease characterized by superficial blistering and erosions of the skin. Literature on PF globally is limited. Understanding the clinicodemographic heterogeneity in PF is crucial for offering improved outcomes for affected individuals.
View Article and Find Full Text PDFCutaneous myiasis in a Serbian traveller returning from Kenya.
Travel Med Infect Dis
September 2025
Department of Veterinary Biosciences, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria 3010, Australia.
Background: Cutaneous myiasis is an ectoparasitic disease caused by fly larvae. In non-endemic regions it is rare, often unfamiliar to clinicians and readily misdiagnosed.
Case Presentation: A 24-year-old Serbian traveller developed painful furuncular lesions on the thigh after returning from Kenya.
Effectiveness and Safety of Orodispersible Budesonide for Eosinophilic Esophagitis: A Multicenter Real-World Study.
Clin Gastroenterol Hepatol
September 2025
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Gastroenterology Unit, Azienda Ospedale Università Padova, Padua, Italy. Electronic address:
Background And Aims: Topical corticosteroids represent one of the effective first-line treatment options for EoE, and therapy with budesonide orodispersible tablets (BOTs) has been recently approved for the treatment of EoE and showed great efficacy in randomized-controlled clinical trials, however real-life data is lacking. Thus, we aimed to evaluate the effectiveness of treatment with BOTs in adult EoE patients in a real-life setting.
Methods: In this prospective study, clinical, histologic, endoscopic, and safety measures were assessed.
[Vitiligo].
Ned Tijdschr Geneeskd
September 2025
Amsterdam UMC, Nederlands Instituut voor Pigmentstoornissen (SNIP), Amsterdam.
Vitiligo is a chronic skin disease characterized by white patches caused by the destruction of melanocytes. The most well-known variant is non-segmental vitiligo, where patches are symmetrically distributed across the entire body, with alternating periods of stability and progression. The white patches arise due to an autoimmune reaction in which cytotoxic T-cells attack the melanocytes.
View Article and Find Full Text PDFTopical Glucocorticoid-Induced Cushing's Syndrome in a Patient with Erythrodermic Psoriasis: A Case Report.
Clin Cosmet Investig Dermatol
September 2025
Department of Dermatology, Wuhan Asia General Hospital, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, 430000, People's Republic of China.
Background: Topical glucocorticoids are widely used in psoriasis treatment but may lead to systemic adverse effects, particularly with prolonged use. While pediatric cases are well-documented, adult-onset iatrogenic Cushing's syndrome from topical corticosteroids remains under-recognized.
Case Presentation: A 31-year-old woman with a 10-year history of psoriasis vulgaris self-administered high-potency clobetasol propionate ointment (monthly cumulative dose escalated from 30 g to 100 g over 22 months) under no physician supervision.